Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer.

Cancer J

From the *Department of Microbiology and Immunology and †Division of Hematology and Medical Oncology, Department of Medicine, James Graham Brown Cancer Center, University of Louisville, Louisville, KY.

Published: September 2014

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells with suppressive properties that preferentially expand in cancer. Myeloid-derived suppressor cells mainly suppress T-cell proliferation and cytotoxicity, inhibit natural killer cell activation, and induce the differentiation and expansion of regulatory T cells. The wide spectrum of MDSC suppressive activity in cancer and its role in tumor progression have rendered these cells a promising target for effective cancer immunotherapy. In this review we briefly discuss the origin of MDSCs and their main mechanisms of suppression and focus more on the approaches developed up to date targeting of MDSCs in tumor-bearing animals and cancer patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3902636PMC
http://dx.doi.org/10.1097/PPO.0000000000000006DOI Listing

Publication Analysis

Top Keywords

myeloid-derived suppressor
12
suppressor cells
12
cancer myeloid-derived
8
cells
6
cancer
5
hampering immune
4
immune suppressors
4
suppressors therapeutic
4
therapeutic targeting
4
targeting myeloid-derived
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!